Sysmex, a major testing equipment manufacturer, reported consolidated net profit of ¥17.0 billion for the April–September period, revising its previous forecast of ¥15.0 billion upward. At the same time, it recognized an impairment loss on a subsidiary, affecting earnings.
Consolidated net profit for the April–September period was ¥17.0 billion, down 11% from the same period a year earlier but above the previous forecast of ¥15.0 billion. Strong sales of testing equipment, particularly in North America, and optimization of selling, general and administrative expenses contributed to the result.
The company determined that the value of a subsidiary that manufactures and sells biochemical testing analyzers had fallen below its carrying value and recognized an impairment loss of ¥5.7 billion. Strong testing equipment sales offset the loss.
The company is still reviewing its full-year earnings forecast for the fiscal year ending March 2027. Revenue is expected to rise 9% year on year to ¥545.0 billion, while net profit is expected to increase 4% to ¥37.0 billion. The announcement of results for the April–September period is scheduled for the 10th.